| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H12N2O4S |
| Molecular Weight | 244.268 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)[C@@H]1CSCN1C(=O)[C@@H]2CCC(=O)N2
InChI
InChIKey=UUTKICFRNVKFRG-WDSKDSINSA-N
InChI=1S/C9H12N2O4S/c12-7-2-1-5(10-7)8(13)11-4-16-3-6(11)9(14)15/h5-6H,1-4H2,(H,10,12)(H,14,15)/t5-,6-/m0/s1
| Molecular Formula | C9H12N2O4S |
| Molecular Weight | 244.268 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Pidotimod is a synthetic dipeptide with immunomodulatory properties. An immunostimulant used in patients with cell-mediated immunodepression during resp and urinary tract infections. In vitro and in vivo laboratory studies show that treatment with pidotimod causes a significant induction of macrophage and neutrophil polymorphonuclear activity, which is characterized by an increase in spontaneous chemotaxis, superoxide anion production and phagocytosis. Several placebo-controlled trials of the drug have been carried out in various indications such as recurrent respiratory, pharyngotonsillar and urinary infections in children, and in adults with exacerbations of chronic bronchitis. For example, in 120 children with recurrent respiratory infections, pidotimod reduced relapse by 35%, hospitalization by 86% and antibiotic use by 47% compared to placebo.
Originator
Approval Year
Doses
PubMed
Patents
Sample Use Guides
Take this medication by mouth, usually 2 to 3 times daily with a full glass of water (8 ounces or 240 milliliters) or as directed by your doctor. Do not lie down for at least 10 minutes after taking this drug.
Route of Administration:
Oral
